Skip to main content

Advertisement

SpringerLink
Log in

Milestones in advanced renal cell carcinoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Renal cell carcinoma (RCC) is a common tumor that is largely refractory to cytotoxic agents. With the implementation of a multitude of novel therapies in the past 10 years, the overall survival of patients with advanced RCC has more than doubled.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer. 2015;136:E359–86.

    Article  CAS  PubMed  Google Scholar 

  2. Kroeger N, Choueiri T, Lee J, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014;65:1086–92.

    Article  PubMed  Google Scholar 

  3. Baldewijns M, Van Vlodrop I, Vermeulen P, et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221:125–38.

    Article  CAS  PubMed  Google Scholar 

  4. Klatte T, Pantuck A. Molecular biology of renal cortical tumors. Urol Clin North Am. 2008;35:573–80.

    Article  PubMed  Google Scholar 

  5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  CAS  PubMed  Google Scholar 

  6. Lee J, Kim M, Park I, et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300–5.

    Article  CAS  PubMed  Google Scholar 

  7. Rini B, Wood L, Elson P, et al. A phase II study of intermittent sunitinib (S) in previously untreated patients (Pts) with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting. J Clin Oncol. 2013;31(Suppl; abstr 4515).

  8. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med. 2013;369:722–31.

    Article  CAS  PubMed  Google Scholar 

  9. Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32:1412–8.

    Article  CAS  PubMed  Google Scholar 

  10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  CAS  PubMed  Google Scholar 

  11. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.

    Article  CAS  PubMed  Google Scholar 

  12. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.

    Article  PubMed  Google Scholar 

  13. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894–906.

    Article  PubMed  Google Scholar 

  14. Voss M, Molina A, Motzer R. M TOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25:835–52.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.

    Article  CAS  PubMed  Google Scholar 

  16. Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.

    Article  CAS  PubMed  Google Scholar 

  17. Grullich C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res. 2014;201:207–14.

    Article  PubMed  Google Scholar 

  18. Zhou L, Liu X, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687–97.

    Article  CAS  PubMed  Google Scholar 

  19. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openlabel, phase 3 trial. Lancet Oncol. 2016;17:917–27.

    Article  CAS  PubMed  Google Scholar 

  20. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–v68.

    Article  CAS  PubMed  Google Scholar 

  21. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–82.

    Article  CAS  PubMed  Google Scholar 

  22. Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and metaanalysis. Eur Urol. 2015;67:740–9.

    Article  PubMed  Google Scholar 

  23. Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomisedphase 2 trial. Lancet Oncol. 2016;17:378–88.

    Article  CAS  PubMed  Google Scholar 

  24. Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866–74.

    Article  CAS  PubMed  Google Scholar 

  25. Ravaud A, Motzer R, Pandha H, et al. Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–54.

    Article  CAS  PubMed  Google Scholar 

  26. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008–16.

    Article  CAS  PubMed  Google Scholar 

  27. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long term response data for 255 patients with metastatic renal cell carcinoma treated with high dose recombinant interleukin 2 therapy. J Clin Oncol. 1996;14:2410–1.

    Article  CAS  PubMed  Google Scholar 

  28. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advancedrenal-cell carcinoma. N Engl J Med. 2015;373:1803–13.

    Article  CAS  PubMed  Google Scholar 

  29. ClinicalTrials.gov. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) 2014. http://clinicaltrials.gov/ct2/show/NCT02231749. Accessed 04.01.2017

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Center for Oncology, Haematology and Palliative Care, Wilhelminenspital, Montleartstraße 37, 1160, Vienna, Austria

    Dora Niedersuess-Beke

Authors
  1. Dora Niedersuess-Beke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dora Niedersuess-Beke.

Ethics declarations

Conflict of interest

D. Niedersuess-Beke declares that she has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niedersuess-Beke, D. Milestones in advanced renal cell carcinoma. memo 10, 38–41 (2017). https://doi.org/10.1007/s12254-017-0321-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-017-0321-9

Keywords

Search

Navigation